Elsevier

Journal of Critical Care

Volume 30, Issue 3, June 2015, Pages 653.e9-653.e17
Journal of Critical Care

A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters,☆☆

https://doi.org/10.1016/j.jcrc.2015.01.014Get rights and content

Abstract

Purpose

The aim of this study was to collect and describe all published reports of local tissue injury or extravasation from vasopressor administration via either peripheral intravenous (IV) or central venous catheter.

Methods

A systematic search of Medline, Embase, and Cochrane databases was performed from inception through January 2014 for reports of adults who received vasopressor intravenously via peripheral IV or central venous catheter for a therapeutic purpose. We included primary studies or case reports of vasopressor administration that resulted in local tissue injury or extravasation of vasopressor solution.

Results

Eighty-five articles with 270 patients met all inclusion criteria. A total of 325 separate local tissue injury and extravasation events were identified, with 318 events resulting from peripheral vasopressor administration and 7 events resulting from central administration. There were 204 local tissue injury events from peripheral administration of vasopressors, with an average duration of infusion of 55.9 hours (± 68.1), median time of 24 hours, and range of 0.08 to 528 hours. In most of these events (174/204, 85.3%), the infusion site was located distal to the antecubital or popliteal fossae.

Conclusions

Published data on tissue injury or extravasation from vasopressor administration via peripheral IVs are derived mainly from case reports. Further study is warranted to clarify the safety of vasopressor administration via peripheral IVs.

Introduction

Vasopressor medications are commonly administered in the emergency department and intensive care unit to treat hemodynamic instability in critically ill patients. Administration of vasopressors via catheters located in large central veins has become the preferred route due to concerns about adverse events resulting from peripheral intravenous (IV) use [1], [2]—especially local tissue ischemia secondary to the vasoconstrictive properties possessed by this class of medications [2].

Despite these concerns, using a peripheral IV to administer vasopressor may allow the medication to reach the patient sooner and reduce the time required to achieve hemodynamic stability and its concomitant clinical benefits. Although peripheral IV access is readily obtained in most patients, peripheral vasopressor administration is often avoided to minimize the risk of potential local tissue ischemia.

In some critically ill patients, the requirement for a central venous catheter (CVC) may delay administration of vasopressors while the catheter is placed (usually by a physician). This delay may have unintended negative consequences because patients must remain in a hemodynamically unstable condition while the CVC is inserted. In addition, CVC insertion during emergency circumstances may increase the risk of adverse events compared with CVC insertion for an elective procedure [3].

The evidence cited for avoiding peripheral administration of vasopressors is a sparse collection of case studies and expert opinion [4]. We sought to describe the literature for the current practice of avoiding peripheral administration of vasopressors due to concerns of local tissue ischemia. We performed a systematic review to describe published reports on local tissue injury or extravasation during the administration of vasopressor medications using a peripheral IV or a CVC, and the type of vasopressor medication infused, the site of administration, and/or the duration of infusion in these events.

Section snippets

Study design and database search

A systematic search was performed on January 17, 2014, using Medline, Embase, and the Cochrane Library databases. A review protocol was not registered or published. The search strategy was formulated with the aid of an experienced research librarian. Although no date restrictions were placed on our search, the dates of coverage at the time of the search were 1946 to 2014 for Medline, 1947 to 2014 for Embase, and 1992 to 2014 for the Cochrane Library. To minimize publication bias, we also did

Characteristics of study subjects

Our search identified a total of 86 371 references, of which 85 [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77],

Studies on peripheral administration of vasopressors

Of the 325 separate events of local tissue injury or vasopressor extravasation associated with administration of vasopressors, 318 events [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [19], [20], [21], [22], [23], [24], [25], [26], [27], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [68], [69],

Limitations

As with any review, our study is limited by reporting bias. Although we have collected published data regarding complications resulting from peripheral and central vasopressor infusion, it is likely some relevant events were not published, which weakens the conclusions of this review. As we searched only for events where complications resulted from administration of vasopressor, we cannot make conclusions comparing the frequency of these complications with instances where no complication

Discussion

Administration of vasopressors is a paramount management strategy in hemodynamically unstable patients [90]. Currently, administration of vasopressors via peripheral IVs is considered by some to be unsafe and is often discouraged, mainly due to concern of local tissue injury [2]. For this reason, administration of vasopressors via CVCs is often advocated [1], [2]. In our systematic review, we have found only observational reports of complications attributable to vasopressor administration via

Conclusions

Vasopressor medications are strong vasoconstrictors that can cause tissue hypoperfusion and injury. Published reports of local tissue injury and extravasation from vasopressor infusion via peripheral IVs are mainly case reports, and may not be representative of true practice. However, based on published reports, the occurrence of local tissue injury requires prolonged administration of vasopressors via peripheral IVs. In emergency situations, short-term administration (< 2 hours) of vasopressor

Acknowledgments

Research librarian Timothy Ruggles contributed to the design and conduct of the search. Mete Erdogan contributed to writing and formatting the final manuscript. Dr Green is supported by a Clinician Scientist Award from the Faculty of Medicine at Dalhousie University in Halifax, Nova Scotia, Canada.

References (90)

  • D.Q. Tran et al.

    Use of stellate ganglion block to salvage an ischemic hand caused by the extravasation of vasopressors

    Reg Anesth Pain Med

    (2005)
  • J. Upton et al.

    Major intravenous extravasation injuries

    Am J Surg

    (1979)
  • R.W. Taylor et al.

    Central venous catheterization

    Crit Care Med

    (2007)
  • A. Jones et al.

    Chapter 6—shock

  • H. Ramadan et al.

    Mechanical and infectious complications developing due to central venous catheterizations in the emergency department

    Med Glas (Zenica)

    (2013)
  • J.D. Ricard et al.

    Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial

    Crit Care Med

    (2013)
  • A. Albillos Martinez et al.

    Cutaneous necrosis caused by vasopressin

    Med Clin (Barc)

    (1985)
  • J.R. Anderson et al.

    Development of cutaneous gangrene during continuous peripheral infusion of vasopressin

    Br Med J (Clin Res Ed)

    (1983)
  • H. Bergmann

    Advantages and disadvantages of prolonged use of nor-epinephrine

    Int J Anesth

    (1953)
  • R.S. Boltax et al.

    Gangrene resulting from infiltrated dopamine solution

    N Engl J Med

    (1977)
  • M.F. Bryant et al.

    Prevention of norepinephrine (levophed) sloughs

    J Med Assoc Ga

    (1957)
  • N. Bunker et al.

    Peripheral administration of vasopressin for catecholamine-resistant hypotension complicated by skin necrosis

    Crit Care Med

    (2006)
  • J.L. Chen et al.

    Extravasation injury associated with low-dose dopamine

    Ann Pharmacother

    (1998)
  • L. Ciesielski

    Skin necrosis of the extremities following the intravenous administration of noradrenalin

    Pol Tyg Lek

    (1963)
  • F. Cioffi et al.

    Superficial gangrene after infusion of noradrenalin substances in patients in hypothermia

    Rass Int Clin Ter

    (1965)
  • A.S. Close et al.

    Cutaneous necrosis due to norepinephrine: analysis of reported cases and surgical treatment

    Wis Med J

    (1958)
  • B.E. Cooper

    High-dose phentolamine for extravasation of pressors

    Clin Pharm

    (1989)
  • E.S. Crawford et al.

    The use of nor-epinephrine in the treatment of hypotension associated with common surgical conditions

    Am Surg

    (1953)
  • M.C. Crocker

    Intravascular guanethidine in the treatment of extravasated vasopressin

    N Engl J Med

    (1981)
  • A.G. Davies et al.

    Extravasation and tissue necrosis secondary to central line infusions

    Anaesthesia

    (2003)
  • R.R. De Alvarez et al.

    Tissue necrosis associated with intravenous norepinephrine administration

    Am Surg

    (1957)
  • E. Delannoy et al.

    A case of operated and recovered pheochromocytoma; cutaneous gangrene caused by intravenous perfusion of adrenalin

    Mem Acad Chir (Paris)

    (1955)
  • R.A. Deterling et al.

    The use of nor-epinephrine (1-arterenol) as a pressor drug with special reference to thoraco-lumbar sympathectomy

    Ann Surg

    (1951)
  • B. Dugger

    Peripheral dopamine infusions: are they worth the risk of infiltration?

    J Intraven Nurs

    (1997)
  • P. Dugois et al.

    Cutaneous necrosis occurring after perfusion of 2 vaso-pressors

    Bull Soc Fr Dermatol Syphiligr

    (1970)
  • R. Dutkowski

    Necrosis of the skin and fingers in the course of noradrenaline administration

    Wiad Lek

    (1966)
  • T. Ebels et al.

    Dopamine-induced ischaemia

    Lancet

    (1977)
  • A.R. Elias Costa et al.

    Cutaneous necrosis caused by noradenaline

    Prensa Med Argent

    (1965)
  • G. Fekete

    Noradrenalin therapy and local complications

    Orv Hetil

    (1957)
  • M. Freer et al.

    Infusion of noradrenaline through the proximal line of a migrated central venous catheter

    Scott Med J

    (2012)
  • H. Fritz et al.

    Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases

    Acta Med Scand

    (1965)
  • H.P. Greenwald et al.

    Tissue necrosis following subcutaneous infiltration with nor-epinephrine; report of two cases

    N Engl J Med

    (1952)
  • R.S. Grewal

    Gangrene following infusion of norepinephrine. Report of a case

    J Int Coll Surg

    (1964)
  • B. Hall

    Recovery of patient in prolonged shock after arterenol therapy

    J Am Med Assoc

    (1955)
  • G.H. Hardie et al.

    Skin necrosis with the intravenous use of norepinephrine

    Med Bull (Ann Arbor)

    (1955)
  • Cited by (162)

    • PRO: Vasopressors Can Be Administered Safely via a Peripheral Intravenous Catheter

      2024, Journal of Cardiothoracic and Vascular Anesthesia
    View all citing articles on Scopus

    Financial support: Dr Green is supported by a Clinician Scientist Award from the Faculty of Medicine at Dalhousie University in Halifax, Nova Scotia, Canada.

    ☆☆

    Conflicts of interest: The authors declare they have no competing interests.

    View full text